Nama's AI scorecard currently rates Centene Buy (5.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is CNC's P/E ratio?

Centene trades at a trailing price-to-earnings ratio of 13.2.

When does CNC report earnings?

Centene's next scheduled report is on Feb 5, 2027. Analysts expect EPS of -$1.12.

What is the CNC price target?

The median analyst price target from 18 analysts is $75.00, with a range of $62.00 – $87.00.

Is CNC Shariah compliant?

Nama's AAOIFI-style screen reads Centene as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Centene (CNC)

Healthcare · Healthcare Plans · NYSE

S&P 500

Centene (CNC) is a Healthcare company in the Healthcare Plans industry. It has a market capitalization of $34.53B, a trailing price-to-earnings ratio of 13.2 and a free-cash-flow yield of 12.6%. Over the most recent reported fiscal year, revenue grew 19.4%. Nama's AI scorecard rates it Buy, 5.8 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Buy · 5.8/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Leading · +75.2% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-29.2%

How far the last close sits under the highest price of the past five years.

Market cap	$34.53B
Trailing P/E	13.2
Price / book	1.6
Price / sales	0.2
FCF yield	12.6%
Dividend yield	—
Gross margin	7.8%
Operating margin	0.8%
Net margin	0.7%
Revenue growth (YoY)	+19.4%
Revenue growth (3-yr annual)	+10.4%
EPS growth (YoY)	-71.1%
FCF/share growth (YoY)	—
Beta	1.1
Exchange	NYSE
Sector	Healthcare
Industry	Healthcare Plans

CNC earnings

Next report: Feb 5, 2027 (Q4 2026, EPS estimate -$1.12). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 27, 2026	$0.58	$0.10	+480.0%	$50.65B
Q2 2026	Jul 28, 2026	$2.51	$1.08	+132.4%	$53.58B
Q1 2026	Apr 28, 2026	$3.37	$2.13	+58.2%	$49.94B
Q4 2025	Feb 6, 2026	-$1.19	-$1.22	+2.5%	$49.73B

CNC analyst price target

Median target $75.00 from 18 analysts, ranging $62.00 – $87.00.

Healthcare Plans peers

Ticker	Company	Market cap	P/E
UNH	UnitedHealth Group	$353.17B	19.3
CVS	CVS Health	$107.28B	10.1
ELV	Elevance Health	$91.96B	14.0
CI	Cigna Group	$77.58B	9.3
HUM	Humana	$52.08B	32.7
MOH	Molina Healthcare	$10.87B	104.5
OSCR	Oscar Health	$9.46B	12.7
PGNY	Progyny	$2.58B	17.0

Explore live CNC data on Nama Insights →

Recent Congressional trades

Centene trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Julia Letlow	House	Sell	$1,001 - $15,000	Jan 13, 2026
Julia Letlow	House	Buy	$1,001 - $15,000	Jan 13, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Sep 12, 2025
Valerie Hoyle	House	Buy	$1,001 - $15,000	Sep 12, 2025
Tim Moore	House	Sell	$100,001 - $250,000	Sep 3, 2025
Tim Moore	House	Buy	$1,001 - $15,000	Sep 3, 2025
Tim Moore	House	Buy	$15,001 - $50,000	Sep 3, 2025
Tim Moore	House	Buy	$15,001 - $50,000	Aug 5, 2025
Tim Moore	House	Buy	$15,001 - $50,000	Aug 5, 2025
Tim Moore	House	Buy	$1,001 - $15,000	Aug 5, 2025
Tim Moore	House	Buy	$15,001 - $50,000	Aug 5, 2025
Tim Moore	House	Buy	$15,001 - $50,000	Aug 5, 2025

CNC FAQ

Is CNC a buy?: Nama's AI scorecard currently rates Centene Buy (5.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is CNC's P/E ratio?: Centene trades at a trailing price-to-earnings ratio of 13.2.
When does CNC report earnings?: Centene's next scheduled report is on Feb 5, 2027. Analysts expect EPS of -$1.12.
What is the CNC price target?: The median analyst price target from 18 analysts is $75.00, with a range of $62.00 – $87.00.
Is CNC Shariah compliant?: Nama's AAOIFI-style screen reads Centene as Not Shariah Compliant. At least one of the three ratios or the industry test failed.